Clinical Study Results
Research Sponsor: AstraZeneca
Drugs studied: Durvalumab and olaparib
Study Purpose: This study was done to learn how well
durvalumab and olaparib work together in
people with advanced bladder cancer
Protocol Number: D933IC00003
Thank you
Thank you for taking part in the clinical study for the study drugs durvalumab and olaparib.
You and all of the participants helped researchers learn more about durvalumab and olaparib
to help people with advanced bladder cancer that can no longer be removed by surgery, also
known as unresectable stage 4 urothelial cancer.
AstraZeneca sponsored this study and believes it is important to share the results of the study
with you and the public. An independent non-profit organization called CISCRP helped prepare
this summary of the study results for you. We hope it helps you understand and feel proud of
your important role in medical research.
If you participated in the study and have questions about the results, please speak with the
study doctor or staff at your study site.
1